VEGFA and hepatocellular carcinoma: For patients with advanced HCC not amenable for resection or local therapies, the recommended first-line therapy is atezolizumab (immune checkpoint inhibitor) plus bevacizumab (humanized monoclonal antibody against anti-vascular endothelial growth factor [VEGF]) [4], with lenvatinib (tyrosine kinase inhibitor) [5] or sorafenib (multi-kinase inhibitor) [6] given as alternatives if contraindications for immune therapies exist [2].